Optimal use of hospital resources and intervention using suPAR for improving prognosis and care for patients with COVID-19

Informazioni relative al progetto

RISCinCOVID

ID dell’accordo di sovvenzione: 961844

DOI 10.3030/961844

Progetto chiuso

Data della firma CE 2 Luglio 2020

Data di avvio 1 Agosto 2020

Data di completamento 31 Luglio 2022

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale € 1 470 057,00

Contributo UE € 884 990,00

Coordinato da

VIROGATES AS
Denmark

Risultati finali

Websites, patent fillings, videos etc. (2)

Dissimination of results

ViroGates will use efforts to dissiminate the results obtained by the consortium. This can be through marketing material, video presentations, presentation at conferences, and through SoMe, e.g. Linkedin etc.

Final data reporting

Final data report and publication of study results

Documents, reports (4)

Study approval

Approval for the conduct of the trial by the first study site (M1)

Approval by ethical committee in countries where suPAR is not already routine

Approval by ethical committee and regulatory authorities in countries where suPAR is not already routine

Reporting of results

Statistical analysis of data Writing of manuscripts Publication in peer reviewed journals and presentations at conferences etc

Registration and consent

HISS will finalize the protocol and the informed consent forms; EudraCT registration; drafting of contracts between investigators and hospital/university administration

Data sets, microdata, etc (1)

Establish suPAR measurements

Set-up of suPAR measurements in 14 Intensive Care Units (ICUs) in Greece. Three of these already have suPAR set-up, but 11 need to have the suPARnostic QT or suPARnostic Turbidimetric assay installed

Open Research Data Pilot (1)

First patient enrolled

Enrolment of the first patient

Pubblicazioni

Peer reviewed articles (3)

Soluble Urokinase Receptor (SuPAR) in COVID-19–Related AKI

Autori: Tariq U. Azam, Husam R. Shadid, Pennelope Blakely, Patrick O’Hayer, Hanna Berlin, Michael Pan, Peiyao Zhao, Lili Zhao, Subramaniam Pennathur, Rodica Pop-Busui, Izzet Altintas, Jens Tingleff, Marius A. Stauning, Ove Andersen, Maria-Evangelia Adami, Nicky Solomonidi, Maria Tsilika, Pinkus Tober-Lau, Eleni Arnaoutoglou, Verena Keitel, Frank Tacke, Athanasios Chalkias, Sven H. Loosen, Evangelos J. G
Pubblicato in: Journal of the American Society of Nephrology, Numero 31/11, 2020, Pagina/e 2725-2735, ISSN 1046-6673
Editore: Lippincott Williams & Wilkins Ltd.
DOI: 10.1681/asn.2020060829

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Autori: Evdoxia Kyriazopoulou, Garyfallia Poulakou, Haralampos Milionis, Simeon Metallidis, Georgios Adamis, Konstantinos Tsiakos, Archontoula Fragkou, Aggeliki Rapti, Christina Damoulari, Massimo Fantoni, Ioannis Kalomenidis, Georgios Chrysos, Andrea Angheben, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Maria Tsilika, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Evan
Pubblicato in: Nature Medicine, 2021, ISSN 1078-8956
Editore: Nature Publishing Group
DOI: 10.1038/s41591-021-01499-z

An open label trial of anakinra to prevent respiratory failure in COVID-19

Autori: Evdoxia Kyriazopoulou, Periklis Panagopoulos, Symeon Metallidis, George N Dalekos, Garyphallia Poulakou, Nikolaos Gatselis, Eleni Karakike, Maria Saridaki, Georgia Loli, Aggelos Stefos, Danai Prasianaki, Sarah Georgiadou, Olga Tsachouridou, Vasileios Petrakis, Konstantinos Tsiakos, Maria Kosmidou, Vassiliki Lygoura, Maria Dareioti, Haralampos Milionis, Ilias C Papanikolaou, Karolina Akinosoglou, D
Pubblicato in: eLife, Numero 10, 2021, ISSN 2050-084X
Editore: eLife Sciences Publications
DOI: 10.7554/elife.66125